We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+9.69%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$3.15B
AUM Growth
+$209M
(+7.1%)
Cap. Flow
+$45.8M
Cap. Flow
% of AUM
1.45%
Top 10 Holdings %
Top 10 Hldgs %
50.35%
Holding
67
New
21
Increased
15
Reduced
10
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HCA Healthcare
HCA
|
+$121M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$117M |
| 3 |
Quest Diagnostics
DGX
|
+$104M |
| 4 |
Elevance Health
ELV
|
+$94.1M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$56.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dentsply Sirona
XRAY
|
+$145M |
| 2 |
Pediatrix Medical
MD
|
+$76.9M |
| 3 |
Agilent Technologies
A
|
+$70.5M |
| 4 |
AbbVie
ABBV
|
+$54.3M |
| 5 |
IQVIA
IQV
|
+$54.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
CALL
AbbVie
ABBV
$443B
| – | – |
-400,000
| Closed | -$37.9M |
|
|
52
AbbVie
ABBV
$443B
| – | – |
-574,070
| Closed | -$54.3M |
|
53
Acadia Pharmaceuticals
ACAD
$4.43B
| – | – |
-1,378,000
| Closed | -$31M |
|
|
AVNS
54
DELISTED
Avanos Medical
AVNS
| – | – |
-627,500
| Closed | -$28.9M |
|
55
Bio-Rad Laboratories Class A
BIO
$8.71B
| – | – |
-102,940
| Closed | -$25.7M |
|
56
Cencora
COR
$60.6B
| – | – |
-424,230
| Closed | -$36.6M |
|
57
Gilead Sciences
GILD
$162B
| – | – |
-656,690
| Closed | -$49.5M |
|
58
Haemonetics
HAE
$3.89B
| – | – |
-497,410
| Closed | -$36.4M |
|
59
CALL
Incyte
INCY
$24.2B
| – | – |
-600,000
| Closed | -$50M |
|
|
60
Incyte
INCY
$24.2B
| – | – |
-130,910
| Closed | -$10.9M |
|
|
61
IQVIA
IQV
$38.7B
| – | – |
-550,930
| Closed | -$54.1M |
|
|
62
Pediatrix Medical
MD
$2.18B
| – | – |
-1,383,200
| Closed | -$76.9M |
|
63
Mettler-Toledo International
MTD
$28.6B
| – | – |
-33,649
| Closed | -$19.3M |
|
64
Puma Biotechnology
PBYI
$404M
| – | – |
-293,130
| Closed | -$19.9M |
|
|
65
Dentsply Sirona
XRAY
$2.68B
| – | – |
-2,875,000
| Closed | -$145M |
|
|
ACOR
66
DELISTED
Acorda Therapeutics
ACOR
| – | – |
-6,413
| Closed | -$18.2M |
|
|
EVHC
67
DELISTED
Envision Healthcare Holdings Inc
EVHC
| – | – |
-814,840
| Closed | -$31.3M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2018 Portfolio in Review
As of Q2 2018, HealthCor Management held 67 positions worth $3.15B, up 7.1% from $2.94B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
HealthCor Management's Q2 2018 filing shows 21 new, 15 increased, 10 reduced and 18 closed positions. Its largest new stake was HCA Healthcare: 1,200,000 shares worth $123M. The largest sale was Dentsply Sirona, an estimated $145M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 90% a quarter earlier.
- HealthCor Management's largest Q2 2018 buy was HCA Healthcare: 1,200,000 shares worth $123M.
- HealthCor Management added most to Elevance Health in Q2 2018, an estimated $94.1M increase.
- HealthCor Management's biggest Q2 2018 reduction was UnitedHealth, cutting an estimated $51.3M.
- HealthCor Management fully exited Dentsply Sirona in Q2 2018, selling an estimated $145M.
- HealthCor Management's ten largest holdings make up 50% of its $3.15B portfolio in Q2 2018.
- HealthCor Management opened 21 new positions and closed 18 in Q2 2018.
- HealthCor Management's portfolio value rose 7.1% quarter-over-quarter to $3.15B.
Based on HealthCor Management's 13F filing for Q2 2018, filed 14 Aug 2018.